The novel TRAIL-receptor agonist APG350 exerts superior therapeutic activity in pancreatic cancer cells

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has raised attention as a novel anticancer therapeutic as it induces apoptosis preferentially in tumor cells. However, first-generation TRAIL-receptor agonists (TRAs), comprising recombinant TRAIL and agonistic receptor-specific antibod...

Descripción completa

Detalles Bibliográficos
Autores principales: Legler, Karen, Hauser, Charlotte, Egberts, Jan-Hendrik, Willms, Anna, Heneweer, Carola, Boretius, Susann, Röcken, Christoph, Glüer, Claus-Christian, Becker, Thomas, Kluge, Michael, Hill, Oliver, Gieffers, Christian, Fricke, Harald, Kalthoff, Holger, Lemke, Johannes, Trauzold, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5906476/
https://www.ncbi.nlm.nih.gov/pubmed/29670075
http://dx.doi.org/10.1038/s41419-018-0478-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5906476/
https://www.ncbi.nlm.nih.gov/pubmed/29670075
http://dx.doi.org/10.1038/s41419-018-0478-0

Ejemplares similares